About Us
Meet The Team
Yann Chong TAN, PhD
Co-Founder and CEO
Co-founded multiple biotech companies which collectively raised more than $400M in funding with successful IPO exit, in which he held various C-suite roles including that of Chief Scientific Officer.
John LEE, MD PhD
Chief Medical Officer
Board-certified cardiologist with extensive clinical development expertise in both pharma and biotech companies and led clinical development programs of a public biotech from Phase I-III.
Robert PIPERNO
Senior Vice President, Tech Ops
Extensive CMC, Manufacturing, and Quality experience in the
pharmaceutical and biopharmaceutical industries for clinical and commercial gene therapies.
Cheryl LEE
Vice President,
Operations
Experienced life science operator and finance leader with more than 15 years of operational experience.
Christian BECK, PhD
Vice President,
Corporate Development
Unique experience in corporate finance, strategy and business development with biopharma transaction experience gained at global investment banks and a biopharma company.
KHOO Shih, PhD
Board Member
Seasoned investor with more than 15 years of experience investing in private and public life sciences and healthcare companies globally.
CEO, ClavystBio
Mia HU, PhD
Board Member
Healthcare investor with global investing and incubator expertise.
Investment Director at Boehringer Ingelheim Venture Fund
Brian BURKE, PhD
Co-Founder and Scientific Advisor
Distinguished cell biologist in the area of the nuclear envelope, including lamins and the LINC complex, through the innovative use of microscopic and biochemical technologies.
W James NELSON, PhD
Scientific Advisor
Eminent cell biologist with seminal contributions in mechanobiology, membrane trafficking and cellular organization.
Professor Emeritus at Stanford University
Colin STEWART, PhD
Co-Founder and Scientific Advisor
Pioneer in techniques underpinning mouse experimental genetics, and developer of multiple mouse models for laminopathies for elucidating mechanisms of disease.
Former Research Director at the Agency for Science, Technology and Research, Singapore
Mark KAY, MD, PhD
Co-Founder and Scientific Advisor
World expert in the area of gene therapy technologies for the treatment of genetic and acquired diseases, including the discovery of novel adeno-associated virus (AAV) capsids.
Head of the Division of Human Gene Therapy; and Professor of Pediatrics and Genetics at Stanford University
Careers
When you're ready, please click: